indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Novavax, SII receive emergency use authorisation for COVID-19 caccine in the Philippines

IMT News Desk
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name COVOVAX Novavax and Serum Institute of India (SII), announced that the Philippine Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. The vaccine will be manufactured and marketed in the Philippines by SII under the brand name COVOVAX. "With less than a third of the Philippine population fully immunised, we expect the option for a protein vaccine, built on a well-understood technology platform, to contribute substantially to increased vaccination rates," said Stanley C Erck, President and CEO, Novavax. "Novavax looks forward to SII's delivery of the vaccine to the Philippines, and with additional authorizations expected elsewhere soon, to helping control the COVID-19 pandemic around the globe." Because the vaccine is stored with standard refrigeration at 2° to 8° Celsius, it may be transported and stored using the existing vaccine supply chain, potentially increasing access in hard-to-reach areas. "The approval of COVOVAX in the Philippines is another step forward in the global fight against the coronavirus," said Adar Poonawalla, CEO, Serum Institute of India. "We are proud to deliver the first protein-based COVID-19 vaccine to the Philippines."  The Novavax/SII vaccine has recently received EUA in Indonesia and the companies have also filed for emergency authorization in India and Emergency Use Listing (EUL) with the World Health Organization (WHO). Novavax also announced regulatory filings for its vaccine in the UK, Australia, New Zealand, Canada and with the WHO, as well as the complete submission of all data and modules in the European Union to support the final regulatory review of its dossier by the European Medicines Agency. 

Recommended

Mykare achieves EBITDA-positive status in elective surgery vertical with 80 per cent revenue growth

Natco Pharma Faces USFDA Scrutiny: 7 Observations at Hyderabad Plant

Nadiad’s DDMM Heart Institute installs real-time cardiac view recognition ultrasound system

India Prepares for 'Disease X' with New National Outbreak Response Team

CitiusTech appoints Navneet Khandelwal as Group CFO

SL Raheja Hospital launches AI-enabled digital PET CT, 3T-MRI and advanced NICU-PICU units

Miltenyi Biotec India, BIRAC sign LoI to advance India’s cell and gene therapy ecosystem

Welcure Secures ₹517 Crore Global Supply Mandate with Thailand’s Fortune Sagar Impex

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions